NO914027L - Fremgangsmaate for fremstilling av nye substituerte azetidinoner - Google Patents

Fremgangsmaate for fremstilling av nye substituerte azetidinoner

Info

Publication number
NO914027L
NO914027L NO91914027A NO914027A NO914027L NO 914027 L NO914027 L NO 914027L NO 91914027 A NO91914027 A NO 91914027A NO 914027 A NO914027 A NO 914027A NO 914027 L NO914027 L NO 914027L
Authority
NO
Norway
Prior art keywords
procedure
preparation
new substituted
substituted azetidinones
azetidinones
Prior art date
Application number
NO91914027A
Other languages
English (en)
Norwegian (no)
Other versions
NO914027D0 (no
Inventor
James B Doherty
Conrad P Dorn
Paul E Finke
William K Hagmann
Malcolm Maccoss
Shrenik K Shah
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/761,191 external-priority patent/US5229381A/en
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of NO914027D0 publication Critical patent/NO914027D0/no
Publication of NO914027L publication Critical patent/NO914027L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO91914027A 1990-10-15 1991-10-14 Fremgangsmaate for fremstilling av nye substituerte azetidinoner NO914027L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59761790A 1990-10-15 1990-10-15
US07/761,191 US5229381A (en) 1983-12-01 1991-09-20 Substituted azetidinones as anti-inflammatory and antidegenerative agents

Publications (2)

Publication Number Publication Date
NO914027D0 NO914027D0 (no) 1991-10-14
NO914027L true NO914027L (no) 1992-04-21

Family

ID=27082866

Family Applications (1)

Application Number Title Priority Date Filing Date
NO91914027A NO914027L (no) 1990-10-15 1991-10-14 Fremgangsmaate for fremstilling av nye substituerte azetidinoner

Country Status (10)

Country Link
EP (1) EP0481671A1 (fr)
JP (1) JPH05132458A (fr)
AU (1) AU648345B2 (fr)
CA (1) CA2052973A1 (fr)
FI (1) FI914833A7 (fr)
IE (1) IE913612A1 (fr)
IL (1) IL99658A0 (fr)
MX (1) MX9101574A (fr)
NO (1) NO914027L (fr)
PT (1) PT99226A (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9103654D0 (en) * 1991-02-21 1991-04-10 Merck Sharp & Dohme Chemical process
WO1993000332A1 (fr) * 1991-06-25 1993-01-07 Merck & Co., Inc. Azetidinones substituees utilisees comme agents antiinflammatoires et antidegeneratifs
US5688785A (en) * 1991-07-23 1997-11-18 Schering Corporation Substituted azetidinone compounds useful as hypocholesterolemic agents
US5688787A (en) * 1991-07-23 1997-11-18 Schering Corporation Substituted β-lactam compounds useful as hypochlesterolemic agents and processes for the preparation thereof
AU658441B2 (en) * 1991-07-23 1995-04-13 Schering Corporation Substituted beta-lactam compounds useful as hypocholesterolemic agents and processes for the preparation thereof
US5149838A (en) * 1991-09-20 1992-09-22 Merck & Co., Inc. Intermediates for substituted azetidinones useful as anti-inflammatory and antidegenerative agents
GB2266527A (en) * 1992-03-17 1993-11-03 Merck & Co Inc Substituted azetidinones useful in the treatment of leukemia
CA2147129A1 (fr) * 1992-10-27 1994-05-11 James B. Doherty Nouvelles azetidinones substituees utilisees comme agents anti-inflammatoires et anti-degeneratifs
CA2108584C (fr) * 1992-10-27 1998-11-24 James B. Doherty Utilisation d'azetidinones substituees comme anti-inflammatoires et agents anti-degeneratifs
US5591737A (en) * 1992-12-17 1997-01-07 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
CA2120221A1 (fr) * 1993-04-23 1994-10-24 Allan W. Rey 2-azetidinones substituees en n
GB9314350D0 (en) * 1993-07-12 1993-08-25 Zeneca Ltd Armide derivatives
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
AU686780B2 (en) * 1994-03-11 1998-02-12 Merck & Co., Inc. Composition for the treatment of lung disease
WO1996019451A1 (fr) * 1994-12-22 1996-06-27 Smithkline Beecham Plc Azetidin-2-ones substituees, destinees au traitement de l'atherosclerose
WO1996029307A1 (fr) * 1995-03-23 1996-09-26 Japan Tobacco Inc. Composes de diphenylmethyle-azetidinone et inhibiteur d'elastase
US5747485A (en) * 1995-04-13 1998-05-05 Merck & Co., Inc. Substituted azetidiones as anti-inflammatory and antidegenerative agents
HUP9901153A3 (en) * 1995-07-01 1999-11-29 Smithkline Beecham Plc Azetidinone derivatives for the treatment of atherosclerosis, their production and pharmaceutical compositions containing them
WO1997013750A1 (fr) * 1995-10-09 1997-04-17 Chiroscience Limited Azetidinones et leur utilisation therapeutique en tant qu'inhibiteurs des cytokines
EP0869943A1 (fr) * 1995-12-08 1998-10-14 Smithkline Beecham Plc Derives de beta-lactame monocycliques utilises dans le traitement de l'atherosclerose
SK127398A3 (en) 1996-03-22 1999-04-13 Du Pont Pharm Co Novel asymmetric synthesis of r-'alpha'-propyl-piperonyl amine and its analogs
CZ341098A3 (cs) * 1996-04-26 1999-03-17 Smithkline Beecham Plc Azetidinonové deriváty pro ošetřování aterosklerózy
US6335324B1 (en) 1998-06-25 2002-01-01 Bristol-Myers Squibb Co. Beta lactam compounds and their use as inhibitors of tryptase
AU4343500A (en) 1999-04-16 2000-11-02 Schering Corporation Use of azetidinone compounds
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
IL156445A0 (en) 2001-01-26 2004-01-04 Schering Corp Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
KR20070120617A (ko) 2001-01-26 2007-12-24 쉐링 코포레이션 치환된 아제티딘온 화합물을 포함하는 약제학적 조성물
BRPI0208384B1 (pt) 2001-03-28 2016-05-31 Merck Sharp & Dohme síntese enantiosseletiva de compostos intermediários de azetidinona
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
EP1429756B1 (fr) 2001-09-21 2006-11-22 Schering Corporation Methodes et combinaisons therapeutiques utiles pour le traitement du xanthome effectue avec des inhibiteurs d'absorption du sterol
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
CA2504916A1 (fr) 2002-11-06 2004-05-27 Schering Corporation Inhibiteurs d'absorption de cholesterol pour le traitement de troubles auto-immuns
DE602004018617D1 (de) 2003-03-07 2009-02-05 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
WO2004081002A1 (fr) 2003-03-07 2004-09-23 Schering Corporation Composes d'azetidinone substitues, leurs formulations et utilisations en vue du traitement de l'hypercholesterolemie
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
WO2004081004A1 (fr) 2003-03-07 2004-09-23 Schering Corporation Composes d'azetidinone substitues, formulations et utilisations de ceux-ci pour traiter l'hypercholesterolemie

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4680391A (en) * 1983-12-01 1987-07-14 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
US4777252A (en) * 1987-08-13 1988-10-11 E. R. Squibb & Sons, Inc. 2-oxo-1-[[(substituted sulfonyl)amino]-carbonyl]azetidines
NZ228600A (en) * 1988-04-11 1992-02-25 Merck & Co Inc 1-(benzylaminocarbonyl)-4-phenoxy-azetidin-2-one derivatives
WO1993000332A1 (fr) * 1991-06-25 1993-01-07 Merck & Co., Inc. Azetidinones substituees utilisees comme agents antiinflammatoires et antidegeneratifs

Also Published As

Publication number Publication date
MX9101574A (es) 1992-06-05
IL99658A0 (en) 1992-08-18
JPH05132458A (ja) 1993-05-28
FI914833A0 (fi) 1991-10-14
CA2052973A1 (fr) 1992-04-16
EP0481671A1 (fr) 1992-04-22
IE913612A1 (en) 1992-04-22
AU8583391A (en) 1991-12-19
FI914833L (fi) 1992-04-16
PT99226A (pt) 1992-09-30
NO914027D0 (no) 1991-10-14
AU648345B2 (en) 1994-04-21
FI914833A7 (fi) 1992-04-16

Similar Documents

Publication Publication Date Title
NO914027D0 (no) Fremgangsmaate for fremstilling av nye substituerte azetidinoner
NO905255D0 (no) Fremgangsmaate for fremstilling av heterocyklisk substituerte acylaminotiazoler.
NO921777D0 (no) Fremgangsmaate for fremstilling av isoparaffiner
NO914429D0 (no) Fremgangsmaate for fremstilling av piperidinylkamfersulfonyloxytocin-antagonister
NO912411D0 (no) Fremgangsmaate for fremstilling av bicykliske heterocykliske forbindelser.
FI912335A0 (fi) Foerfarande foer framstaellning av rikligt med fastaemnen innehaollande uppslamningar.
NO905008L (no) Fremgangsmaate for fremstilling av heterocykliske forbindelser.
NO904059L (no) Fremgangsmaate for fremstilling av nye substituerte isokinoliner.
NO903431D0 (no) Fremgangsmaate for fremstilling av kromanderivater.
NO901813L (no) Fremgangsmaate for fremstilling av nye tieno-triazolo-diazepin-derivater.
NO913391D0 (no) Fremgangsmaate for fremstilling av nye hetrazepinoide syreamider.
NO914504D0 (no) Fremgangsmaate for fremstilling av dietere
NO920049D0 (no) Fremgangsmaate for fremstilling av 3-eksometylencefamsulfoksydestere
NO914053L (no) Fremgangsmaate for fremstilling av 8-klorokinolonderivater
NO911118D0 (no) Fremgangsmaate for fremstilling av nye 8-sulfamylmethylen-2-amino-tetraliner.
NO904069D0 (no) Fremgangsmaate for fremstilling av nye alkanofenoner.
NO910782L (no) Nye krystallinske former av (s)-norfluoksetin-hydroklorin.
NO914985L (no) Fremgangsmaate for fremstilling av 15-nitro-tabersonin-derivater
NO914452L (no) Fremgangsmaate for fremstilling av isokinolinderivater
NO893006D0 (no) Fremgangsmaate for fremstilling av nye allylaminoetylazoler
NO174196C (no) Fremgangsmåte for fremstilling av omega-decenol
NO911665L (no) Fremgangsmaate for fremstilling av nye nojirimycinderivater
NO902293L (no) Fremgangsmaate for fremstilling av nye tiazepinderivater.
NO914586L (no) Fremgangsmaate for fremstilling av polyeterester
NO177592C (no) Nye mellomprodukter for fremstilling av carbapenemderivater